Etter Jean-François, Stapleton John A
Institute of Social and Preventive Medicine, University of Geneva, Geneva, Switzerland.
Tob Control. 2006 Aug;15(4):280-5. doi: 10.1136/tc.2005.015487.
To assess if the effect of a single treatment episode with nicotine replacement therapy (NRT) enhances smoking cessation over many years.
Meta-analysis of all randomised controlled trials of NRT with final follow-up more than one year after the start of treatment. Twelve eligible trials were identified, all placebo-controlled, having final follow-ups ranging from 2-8 years. All had earlier follow-ups at 12 months. They comprised 2408 active and 2384 placebo treatment participants.
The odds ratio (OR) in favour of NRT at final follow-up was 1.99 (95% confidence interval (CI) 1.50 to 2.64). There was no evidence that the effect varied according to length of final follow-up (beta = 0.92, p = 0.28) or duration of initial NRT treatment (beta = 0.99, p > 0.5). The overall relapse rate between the 12 months and final follow-up was 30.0% (95% CI 23.5% to 37.5%). This rate did not differ between NRT and control groups (OR 1.11, 95% CI 0.78 to 1.59), or length of initial NRT treatment. There was also no evidence that it varied according to length of final follow up. Due to relapse, the overall efficacy of NRT treatment in terms of additional ex-smokers declined from 10.7% over and above placebo (6.6% to 14.8%) after one year to 7.2% (3.8% to 11.3%) at an average of 4.3 years follow up.
The relative efficacy of a single course of NRT remains constant over many years. The majority of relapse after 12 months occurs within the first or second year and is not detectable thereafter, suggesting that NRT has a permanent effect on smoking cessation. However, initial relapse after one year has the effect of diminishing the number of ex-smokers that can be ultimately attributed to NRT. Results after only 6-12 months of follow-up, as used in existing reviews and treatment guidelines, will overestimate the lifetime benefit and cost-efficacy of NRT by about 30%. Because the long-term benefit of NRT is modest, tobacco dependence treatment might be better viewed as a chronic disorder, requiring repeated episodes of treatment.
评估尼古丁替代疗法(NRT)单次治疗疗程的效果是否能在多年内提高戒烟成功率。
对所有NRT随机对照试验进行荟萃分析,治疗开始后最终随访时间超过一年。共识别出12项符合条件的试验,均为安慰剂对照试验,最终随访时间为2至8年。所有试验在12个月时均有早期随访。试验包括2408名接受活性治疗的参与者和2384名接受安慰剂治疗的参与者。
最终随访时支持NRT的优势比(OR)为1.99(95%置信区间(CI)1.50至2.64)。没有证据表明效果会因最终随访时间的长短(β = 0.92,p = 0.28)或初始NRT治疗的持续时间(β = 0.99,p > 0.5)而有所不同。12个月至最终随访期间的总体复发率为30.0%(95% CI 23.5%至37.5%)。该复发率在NRT组和对照组之间没有差异(OR 1.11,95% CI 0.78至1.59),也与初始NRT治疗的持续时间无关。同样没有证据表明它会因最终随访时间的长短而有所不同。由于复发,NRT治疗在额外戒烟者方面的总体疗效从一年后高于安慰剂的10.7%(6.6%至14.8%)下降到平均4.3年随访时的7.2%(3.8%至11.3%)。
NRT单一疗程的相对疗效在多年内保持不变。12个月后的大多数复发发生在第一年或第二年,此后无法检测到,这表明NRT对戒烟有持久影响。然而,一年后的初始复发会减少最终可归因于NRT的戒烟者数量。现有综述和治疗指南中使用的仅6至12个月的随访结果将高估NRT的终身益处和成本效益约30%。由于NRT的长期益处不大,烟草依赖治疗可能更好地被视为一种慢性疾病,需要反复进行治疗。